Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results

Reviva Pharmaceuticals Holdings ( (RVPH) ) just unveiled an update.

Reviva Pharmaceuticals announced positive preliminary topline data from the open-label extension portion of its Phase 3 RECOVER trial for brilaroxazine in schizophrenia. The findings demonstrate robust long-term efficacy and safety, with significant improvements in symptom domains and no major safety concerns, supporting brilaroxazine’s potential as a promising treatment for schizophrenia.

More about Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing therapies to address unmet medical needs in central nervous system, inflammatory, and cardiometabolic diseases. The company is advancing its lead drug candidate, brilaroxazine, which has shown potential in treating schizophrenia, psoriasis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.

YTD Price Performance: -49.32%

Average Trading Volume: 1,189,003

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $87.28M

For a thorough assessment of RVPH stock, go to TipRanks’ Stock Analysis page.